Mostrar el registro sencillo del ítem
Supervivencia de pacientes con diagnóstico de cáncer de pulmón en Bucaramanga y su área metropolitana en el periodo 2012–2016
dc.contributor.advisor | Uribe Pérez, Claudia Janeth | |
dc.contributor.advisor | Hormiga Sánchez, Claudia Milena | |
dc.contributor.author | Rueda Perea, María Alejandra | |
dc.coverage.spatial | Bucaramanga (Santander, Colombia) | spa |
dc.coverage.temporal | 2012-2016 | spa |
dc.date.accessioned | 2022-07-11T21:01:05Z | |
dc.date.available | 2022-07-11T21:01:05Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/16905 | |
dc.description.abstract | El cáncer de pulmón (CP) es una de las neoplasias malignas de mayor frecuencia y mortalidad, se estima que para el 2020 hubo 2,2 millones de casos nuevos y 1,8 millones de muertes por cáncer de pulmón a nivel mundial. Es la segunda causa más frecuente de cáncer para ambos sexos y la primera causa de muerte por cáncer según el registro mundial de GLOBOCAN para el año 2020 (1). En Colombia para el 2020 según GLOBOCAN, se presentaron 6876 casos de CP (6,1%), ocupando el quinto puesto en incidencia; y 6090 muertes por CP (11,1%) para ambos sexos en todas las edades, ocupando el segundo puesto (1). Se dispone de estudios de sobrevida para cáncer de pulmón basados en registros poblacionales de cáncer, para las ciudades de Cali (2) y Manizales (3) , sin embargo, a la fecha no se cuenta con estudios de sobrevida en la población de Bucaramanga y el área metropolitana. Objetivo: Determinar la supervivencia a 12, 24 y 36 meses en las personas residentes del Área Metropolitana de Bucaramanga con diagnóstico de cáncer de pulmón durante los años 2012 y 2016. | spa |
dc.description.tableofcontents | Resumen ...................................................................................................................................................... 9 Introducción ............................................................................................................................................... 16 Planteamiento Y Justificación Del Problema........................................................................................ 17 Objetivos .................................................................................................................................................... 19 Objetivo General ....................................................................................................................................... 19 Objetivos Específicos ............................................................................................................................... 19 Marco Teórico ........................................................................................................................................... 20 Datos Sociodemográficos ....................................................................................................................... 20 Etiología Y Factores De Riesgo ............................................................................................................. 22 Manifestaciones Clínicas ......................................................................................................................... 25 Tamizaje ..................................................................................................................................................... 27 Diagnóstico ................................................................................................................................................ 29 Tratamiento ................................................................................................................................................ 35 Incidencia Y Mortalidad Por Cáncer De Pulmón ................................................................................. 38 Supervivencia ............................................................................................................................................ 51 Descripción Demográfica De La Población En La Región Del Estudio ........................................... 53 Estado Del Arte ......................................................................................................................................... 54 Metodología ............................................................................................................................................... 62 Tipo De Estudio ........................................................................................................................................ 62 Población Y Muestra ................................................................................................................................ 62 Criterios De Inclusión Y Exclusión ......................................................................................................... 62 Variables .................................................................................................................................................... 63 Recolección De La Información ............................................................................................................. 63 Procesamiento Y Control De Calidad De Los Datos .......................................................................... 65 Análisis De Datos ..................................................................................................................................... 65 Consideraciones Éticas ........................................................................................................................... 67 Resultados ................................................................................................................................................. 69 Participantes .............................................................................................................................................. 69 Características Sociodemográficas De Los Casos De Cáncer De Pulmón Incluidos En El Análisis De Sobrevida .............................................................................................................................. 70 Características Sociodemográficas De Los Casos De Cáncer De Pulmón Excluidos En El Análisis De Sobrevida .............................................................................................................................. 72 Características Clínicas De Los Casos De Cáncer De Pulmón ........................................................ 75 Incidencia De Cáncer De Pulmón En Bucaramanga Y Su Área Metropolitana Entre 2012 Y 2016 ..................................................................................................................................................................... 80 Supervivencia: Incidencia Acumulada Y Tiempos De Supervivencia. ............................................. 81 Función De Supervivencia Global Por Cáncer De Pulmón ................................................................ 82 Discusión .................................................................................................................................................... 97 Conclusiones ........................................................................................................................................... 110 Limitaciones ............................................................................................................................................. 112 Anexos...................................................................................................................................................... 114 Bibliografía ............................................................................................................................................... 116 | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | * |
dc.title | Supervivencia de pacientes con diagnóstico de cáncer de pulmón en Bucaramanga y su área metropolitana en el periodo 2012–2016 | spa |
dc.title.translated | Survival of patients diagnosed with lung cancer in Bucaramanga and its metropolitan area in the period 2012-2016 | spa |
dc.degree.name | Especialista en Medicina Interna | spa |
dc.publisher.grantor | Universidad Autónoma de Bucaramanga UNAB | spa |
dc.rights.local | Abierto (Texto Completo) | spa |
dc.publisher.faculty | Facultad Ciencias de la Salud | spa |
dc.publisher.program | Especialización en Medicina Interna | spa |
dc.description.degreelevel | Especialización | spa |
dc.type.driver | info:eu-repo/semantics/masterThesis | |
dc.type.local | Tesis | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_bdcc | |
dc.subject.keywords | Internal medicine | spa |
dc.subject.keywords | Medicine | spa |
dc.subject.keywords | Medical sciences | spa |
dc.subject.keywords | Health sciences | spa |
dc.subject.keywords | Lung cancer | spa |
dc.subject.keywords | Morbidity and mortality | spa |
dc.subject.keywords | Survival | spa |
dc.subject.keywords | Sociodemographic factors | spa |
dc.subject.keywords | Clinical factors | spa |
dc.subject.keywords | Neoplasms | spa |
dc.subject.keywords | Demographic profile | spa |
dc.subject.keywords | Population dynamics | spa |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga - UNAB | spa |
dc.identifier.reponame | reponame:Repositorio Institucional UNAB | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.relation.references | 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. | spa |
dc.relation.references | 2. Bravo LE, García LS, Collazos PA. Cancer survival in Cali, Colombia: A population base study, 1995 - 2004. Colomb Med. 2014;45(2):110–6. | spa |
dc.relation.references | 3. Arias-Ortiz NE, de Vries E. Health inequities and cancer survival in Manizales, Colombia: A population-based study. Colomb Med. 2018;49(1):63–72. | spa |
dc.relation.references | 4. Estupefacientes DN de. Consumo de sustancias psicoactivas en Colombia. Minist Justicia Colomb [Internet]. 1996;(2):109. Available from: https://www.minjusticia.gov.co/programas co/ODC/Documents/Publicaciones/Consumo/Estudios/Nacionales/CO03301996 estudio-nacional-sobre-consumo-sustancias-psicoactivas-colombia-.pdf | spa |
dc.relation.references | 5. Pardo C, Vries EDE, Buitrago L. Atlas de mortalidad por cáncer en Colombia. Cuarta edi. Bogotá: Instituto Nacional de Cancerología - ESE; 2017. 120 pages | spa |
dc.relation.references | 6. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet [Internet]. 2015;385(9972):977–1010. Available from: http://dx.doi.org/10.1016/S0140-6736(14)62038-9 | spa |
dc.relation.references | 7. Pardo C, Cendales R. Estimaciones de incidencia y mortalidad para los principales cinco tipos de cáncer en Colombia, 2007-2011. Colomb Med. 2018;49(1):16–22. | spa |
dc.relation.references | 8. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med [Internet]. 2020;41(1):1–24. Available from: https://doi.org/10.1016/j.ccm.2019.10.001 | spa |
dc.relation.references | 9. Jeon J, Holford TR, Levy DT, Feuer EJ, Cao P, Tam J, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: A comparative modeling approach. Ann Intern Med. 2018;169(10):684–93 | spa |
dc.relation.references | 10. Donington JS, Colson YL. Sex and Gender Differences in Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg [Internet]. 2011;23(2):137–45. Available from: http://dx.doi.org/10.1053/j.semtcvs.2011.07.001 | spa |
dc.relation.references | 11. Kligerman S, White C. Epidemiology of lung cancer in women: Risk factors, survival, and screening. Am J Roentgenol. 2011;196(2):287–95. | spa |
dc.relation.references | 12. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19 | spa |
dc.relation.references | 13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. | spa |
dc.relation.references | 15. Hastert TA, Beresford SAA, Sheppard L, White E. Disparities in cancer incidence and mortality by area-level socioeconomic status: A multilevel analysis. J Epidemiol Community Health. 2015;69(2):168–76 | spa |
dc.relation.references | 16. Nasim F, Sabath BF, Eapen GA. Lung Cancer. Med Clin North Am [Internet]. 2019;103(3):463–73. Available from: https://doi.org/10.1016/j.mcna.2018.12.006 | spa |
dc.relation.references | 17. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health. 1987;77(4):425–31 | spa |
dc.relation.references | 18. Agents Classified by the IARC Monographs , Volumes 1 – 116 [Internet]. World Health Organization. 2016 [cited 2021 Nov 13]. p. 1–36. Available from: https://monographs.iarc.who.int/list-of-classifications/ | spa |
dc.relation.references | 19. Dwight T. Janerich, D.D.S., M.P.H. WD. Lung cancer and exposure to tobacco smoke in the household. New English J Med. 1990;323(16):1120–3 | spa |
dc.relation.references | 20. World Health Organization. Air pollution and cancer. IARC Scientific Publication [Internet]. Straif K, Cohen A SJ, editor. IARC scientific publications. 177 p. Available from: https://www.iarc.who.int/wp content/uploads/2018/07/AirPollutionandCancer161.pdf | spa |
dc.relation.references | 21. Lubin JH, Boice JD, Edling C, Hornung RW, Howe GR, Kunz E, et al. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. J Natl Cancer Inst. 1995;87(11):817–27. | spa |
dc.relation.references | 22. Fingerhut M, Driscoll T, Nelson DI, Concha-Barrientos M, Punnett L, Pruss-Ustin A, et al. Contribution of occupational risk factors to the global burden of disease - A summary of findings. Scand J Work Environ Heal Suppl. 2005;(1):58–61. | spa |
dc.relation.references | 23. Steenland K, Burnett C, Lalich N, Ward E, Hurrell J. Dying for work: The magnitude of us mortality from selected causes of death associated with occupation. Am J Ind Med. 2003;43(5):461–82. | spa |
dc.relation.references | 24. American Cancer Society. American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021. 2021. p. 1–72 | spa |
dc.relation.references | 25. Velmurugan KR, Varghese RT, Fonville NC, Garner HR. High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification Oncogene [Internet]. 2017;36(46):6383–90. Available from: http://dx.doi.org/10.1038/onc.2017.256 | spa |
dc.relation.references | 26. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007;176(3):285–90. 27 | spa |
dc.relation.references | 27. Syrjänen KJ. Bronchial Squamous cell carcinomas associated with epithelial changes identical to condylomatous lesions of the uterine cervix. Lung. 1980;142:131–42 | spa |
dc.relation.references | 28. Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumoniae and lung cancer: Epidemiologic evidence. Cancer Epidemiol Biomarkers Prev. 2005;14(4):773–8. | spa |
dc.relation.references | 29. Walling AM, Weeks JC, Kahn KL, Tisnado D, Keating NL, Dy SM, et al. Symptom Prevalence in Lung and Colorectal Cancer Patients. J Pain Symptom Manage. 2015;49(2):192–202 | spa |
dc.relation.references | 30. Hoy H, Lynch T, Beck M. Surgical Treatment of Lung Cancer. Crit Care Nurs Clin North Am [Internet]. 2019;31(3):303–13. Available from: https://doi.org/10.1016/j.cnc.2019.05.002 | spa |
dc.relation.references | 31. Albert Schweitzer Hospital, Lambarene, Gabon, and Institute of Tropical Medicine, University of Tübingen, Tübingen G. Reduced Lung-Cancer mortality with low dose computed tomographic scanning. N Engl J Med. 2011;365:687–96 | spa |
dc.relation.references | 32. Ministerio de Salud y Protección Social, Colciencias, Instituto de Evaluación Tecnológica en Salud & IN de C-E. Guía de Práctica Clínica para la detección temprana, diagnóstico, estadificación y tratamiento del cáncer de pulmón. Guía para pacientes y cuidadores o padres y cuidadores. 2014;(36). | spa |
dc.relation.references | 33. Kutob L, Schneider F. Lung Cancer Staging. Surg Pathol Clin [Internet]. 2020;13(1):57–71. Available from: https://doi.org/10.1016/j.path.2019.10.003 | spa |
dc.relation.references | 34. Hirsch FR, Scagliotti G V., Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet [Internet]. 2017;389(10066):299–311. Available from: http://dx.doi.org/10.1016/S0140 6736(16)30958-8 | spa |
dc.relation.references | 35. Pignon JP, Tribodet H, Scagliotti G V., Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–9. | spa |
dc.relation.references | 36. Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, Rodríguez-Martínez Á, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: Frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506–18 | spa |
dc.relation.references | 38. Bray F, Piñeros M. Cancer patterns, trends and projections in latin america and the caribbean: A global context. Salud Publica Mex. 2016;58(2):104–17 | spa |
dc.relation.references | 39. Piñeros M, Ferlay J, Murill R. Cancer incidence estimates at the national and district levels in Colombia. Salud Publica Mex. 2006;48(6):455–65 | spa |
dc.relation.references | 40. Ospina M ML. Observatorio Nacional de Cáncer Colombia. Rev Fac Nac Salud Pública. 2015;33(2). | spa |
dc.relation.references | 41. Hernández G. Epidemiología del cáncer en Colombia: Una transición que debemos conocer. Rev Med [Internet]. 2021;43(1):64–73. Available from: https://revistamedicina.net/ojsanm/index.php/Medicina/article/view/1586/2031 | spa |
dc.relation.references | 42. Pérez CJU, Gómez SES, Sánchez CMH. Cancer incidence and mortality in Bucaramanga, Colombia. 2008-2012. Colomb Med. 2018;49(1):73–80. | spa |
dc.relation.references | 43. Yépez MC, Jurado DM, Bravo LM, Bravo LE. Trends in cancer incidence, and mortality in pasto, Colombia. 15 years experience. Colomb Med. 2018;49(1):42–54 | spa |
dc.relation.references | 44. World Health Organization. Cancer survival in Africa, Asia, the Caribbean and Central America. Introduction. IARC scientific publications. 2011. p. 1–5 | spa |
dc.relation.references | 45. DANE & CNPV. Resultados Colombia Censo 2018. Dep Nac Estadística [Internet]. 2018;1. Available from: https://www.dane.gov.co/files/censo2018/infografias/info CNPC-2018total-nal-colombia.pdf | spa |
dc.relation.references | 46. Lin HT, Liu FC, Wu CY, Kuo CF, Lan WC, Yu HP. Epidemiology and survival outcomes of lung cancer: A population-based study. Biomed Res Int. 2020;2019. | spa |
dc.relation.references | 47. Lachgar A, Tazi MA, Afif M, Er-Raki A, Kebdani T, Benjaafar N. Le cancer du poumon : incidence et survie à Rabat, Maroc. Rev Epidemiol Sante Publique [Internet]. 2016;64(6):391–5. Available from: http://dx.doi.org/10.1016/j.respe.2016.02.012 | spa |
dc.relation.references | 48. Morales Sánchez L, Gassiot Nuño C, Nenínger Vinageras E, Prior García A, Rodríguez Vázquez JC. Supervivencia de pacientes con carcinoma broncógeno en el Hospital “Hermanos Ameijeiras” de 1997-2002. Rev Cubana Med. 2009;48(3):15–27 | spa |
dc.relation.references | 49. Soto AVA. Sobrevida en pacientes con cáncer de pulmón en el Hospital Oncológico del Estado de Sonora en el periodo comprendido de 1999 a 2006. Universidad de Sonora; 2011. | spa |
dc.relation.references | 50. Elkbuli A, Byrne MM, Zhao W, Sutherland M, McKenney M, Godinez Y, et al. Gender disparities in lung cancer survival from an enriched Florida population based cancer registry. Ann Med Surg [Internet]. 2020;60(December):680–5. Available from: https://doi.org/10.1016/j.amsu.2020.11.081 | spa |
dc.relation.references | 51. Argumero CD. SUPERVIVENCIA DE LOS PACIENTES CON CÁNCER DE PULMÓN EN EL HOSPITAL MILITAR CENTRAL. BOGOTÁ-COLOMBIA, 2007 2014. Universidad el Bosque; 2017. | spa |
dc.relation.references | 52. Diego Mauricio Gonzalez Ramirez, Jose Fidel Tatis Méndez, Doris Cardona Arango HIGG. Supervivencia de los pacientes con cáncer de pulmón estadio III y metastásico atendidos en el Instituto de Cancerología (IDC) Las Américas de Medellín, Colombia 2014 – 2018. Vol. 1. Universidad CES Medellin; 2019. | spa |
dc.relation.references | 53. Cardona AF, Carranza H, Vargas CA, Otero JM, Reveiz L, Reguart N, et al. Supervivencia de pacientes con cáncer de pulmón de célula no pequeña en cuatro instituciones de Colombia. Rev Venez Oncol. 2010;22(1):66–83. | spa |
dc.relation.references | 54. Otero JM, Cardona AF, Revéiz L, Campo F, Carranza H, Vargas CA, et al. Supervivencia en pacientes con adenocarcinoma de pulmón metastásico y registro de las primeras mutaciones en el receptor para el factor de crecimiento epidérmico documentado en Colombia: Estudio del ONCOLGroup. Acta Médica Colomb. 2009;34(2):55–65. | spa |
dc.contributor.cvlac | Uribe Pérez, Claudia Janeth [0000267848] | spa |
dc.contributor.googlescholar | Uribe Pérez, Claudia Janeth [hx8PM4AAAAAJ] | spa |
dc.contributor.scopus | Uribe Pérez, Claudia Janeth [55546023800] | spa |
dc.subject.lemb | Medicina interna | spa |
dc.subject.lemb | Medicina | spa |
dc.subject.lemb | Ciencias médicas | spa |
dc.subject.lemb | Neoplasmas | spa |
dc.subject.lemb | Perfil demográfico | spa |
dc.subject.lemb | Dinámica de la población | spa |
dc.identifier.repourl | repourl:https://repository.unab.edu.co | spa |
dc.description.abstractenglish | Lung cancer is one of the malignant neoplasms with the highest frequency and mortality, it is estimated that by 2020 there were 2.2 million new cases and 1.8 million deaths from lung cancer worldwide. It is the second most frequent cause of cancer for both sexes and the first cause of cancer death according to the GLOBOCAN world registry for 2020 (1). According to GLOBOCAN, in Colombia for 2020 there were 6,876 cases of lung cancer (6.1%), ranking fifth in incidence; and 6,090 deaths from lung cancer (11.1%) for both sexes at all ages, ranking second (1). Survival studies for lung cancer based on population cancer registries are available for the cities of Cali (2) and Manizales (3), however, to date there are no survival studies in the population of Bucaramanga and the metropolitan area. Objective: To determine survival in residents of the metropolitan area of Bucaramanga diagnosed with lung cancer at 12, 24 and 36 from 2012 to 2016. | spa |
dc.subject.proposal | Ciencias de la salud | spa |
dc.subject.proposal | Cáncer de pulmón | spa |
dc.subject.proposal | Morbimortalidad | spa |
dc.subject.proposal | Supervivencia | spa |
dc.subject.proposal | Factores sociodemográficos | spa |
dc.subject.proposal | Factores clínicos | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/TM | |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa | spa |
dc.coverage.campus | UNAB Campus Bucaramanga | spa |
dc.description.learningmodality | Modalidad Presencial | spa |